Pharmafile Logo

cancer drugs pricing

- PMLiVE

Our Work With Mind

In celebration of Mental Health Awareness Week 2023, we're sharing some of our recent work with Mind.

Mednet Group

Train your brain for success

In this episode of Impetus Digital‘s Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital sits down with Max Newlon, President of Brain Co. They discuss everything from...

Impetus Digital

- PMLiVE

Novartis’ Cosentyx recommended by CHMP for hidradenitis suppurativa

An estimated one in 100 people globally are affected by the inflammatory skin disease

- PMLiVE

Novartis announces positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the disease

Mednet Mental Health Strategy 2023

We've launched our mental health strategy for the year to support our colleagues in maintaining positive mental health.

Mednet Group

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

- PMLiVE

Mental health in PR: New industry-wide CPD-accredited training programme launches to help manage work-related pressure and stress

Fox&cat, CIPR, PRCA and HCA launch Under the tree: a free training programme designed to equip agency, in-house and independent communications practitioners with the skills they need to manage work-related...

Fox&Cat

- PMLiVE

Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients

An estimated one in 100 people globally are affected by the inflammatory skin disease

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

Around 82.3% of patients achieved haemoglobin-level increases of 2g/dL or more from baseline

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The study met its primary endpoint of radiographic progression-free survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links